Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/18013
Full metadata record
DC FieldValueLanguage
dc.contributor.authorElisaf, M. S.en
dc.contributor.authorTheodorou, J.en
dc.contributor.authorPappas, C.en
dc.contributor.authorSiamopoulos, K.en
dc.date.accessioned2015-11-24T18:49:53Z-
dc.date.available2015-11-24T18:49:53Z-
dc.identifier.issn0008-6312-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/18013-
dc.rightsDefault Licence-
dc.subjectAgeden
dc.subjectAngiotensin-Converting Enzyme Inhibitors/adverse effects/*therapeutic useen
dc.subjectBlood Pressure/drug effects/physiologyen
dc.subjectCaptopril/adverse effects/*therapeutic useen
dc.subjectDose-Response Relationship, Drugen
dc.subjectDrug Administration Scheduleen
dc.subjectFemaleen
dc.subjectHeart Failure/*drug therapy/physiopathologyen
dc.subjectHeart Rate/drug effects/physiologyen
dc.subjectHumansen
dc.subjectHyponatremia/*drug therapy/physiopathologyen
dc.subjectKidney Concentrating Ability/drug effects/physiologyen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectPotassium/blooden
dc.subjectPrognosisen
dc.subjectProspective Studiesen
dc.subjectSodium/blooden
dc.titleSuccessful treatment of hyponatremia with angiotensin-converting enzyme inhibitors in patients with congestive heart failureen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/7585758-
heal.identifier.secondaryhttp://content.karger.com/ProdukteDB/produkte.asp?doi=10.1159/000176926-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate1995-
heal.abstractHyponatremia commonly complicates the clinical course of patients with congestive heart failure (CHF) and seems to be an ominous prognostic factor. Angiotensin-converting enzyme (ACE) inhibitors improve the symptomatology of CHF patients. Moreover, it has been reported that these drugs can raise serum sodium in hyponatremic patients. The aim of this prospective work was to study the mechanisms involved in the correction of hyponatremia in 6 patients aged 52-69 years with CHF and hyponatremia (serum sodium 125-128 mmol/l) who were receiving digitalis and furosemide. In these patients, captopril was introduced in progressively increasing doses. The drug induced significant clinical improvement. Additionally, a statistically significant increase in serum sodium was observed which was correlated to a rise in the diluting ability of the kidney (increase in CeH2O). A slight increase in creatinine clearance was also found, which could have contributed to the improvement in hyponatremia. Therefore, we conclude that ACE inhibitors can improve hyponatremia in CHF patients by increasing the urinary diluting ability.en
heal.journalNameCardiologyen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Files in This Item:
There are no files associated with this item.


This item is licensed under a Creative Commons License Creative Commons